Get the Stockscreener App
7.06
8.19%
-0.63
After Hours:
7.11
0.05
+0.71%
Organon Co stock is traded at $7.06, with a volume of 12.63M.
It is down -8.19% in the last 24 hours and down -13.05% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$7.69
Open:
$6.7
24h Volume:
12.63M
Relative Volume:
2.19
Market Cap:
$1.84B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
2.6224
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
-12.84%
1M Performance:
-13.05%
6M Performance:
-21.99%
1Y Performance:
-51.97%
1-Day Range:
$6.50
$7.28
1-Week Range:
$6.50
$8.43
52-Week Range:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
7.06 | 2.00B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,038.27 | 908.63B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
244.55 | 580.30B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
227.50 | 390.40B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
204.52 | 317.44B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
161.18 | 305.42B | 54.72B | 14.02B | 15.32B | 7.1855 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon & Co To Go Ex-Dividend On February 23rd, 2026 With 0.02 USD Dividend Per Share - 富途牛牛
Organon Earnings Call Balances Stability With Rising Risks - TipRanks
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - simplywall.st
Organon Shares Slide on Quarterly Loss and Cautious Outlook - AD HOC NEWS
Organon (OGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Organon & Co. (NYSE:OGN) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Organon: Overview of Fourth Quarter Financial Results - Bitget
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Organon Q4 Earnings ReviewPoor Results Trigger Predictable Sell-Off (NYSE:OGN) - Seeking Alpha
Organon sees FY26 revenue $6.2B, consensus $6.11B - TipRanks
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
Organon reports Q4 adjusted EPS 63c, consensus 73c - TipRanks
Organon Shares Fall After 4Q Earnings Miss Expectations - 富途牛牛
Organon & Co. (NYSE:OGN) Shares Gap Down Following Weak Earnings - MarketBeat
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
OGN: 2025 results show stable revenue and EBITDA, with 2026 guidance flat amid margin and policy headwinds - TradingView
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss By Investing.com - Investing.com India
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com
Organon Co earnings missed by $0.13, revenue fell short of estimates By Investing.com - Investing.com Canada
Organon Co earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Organon Q4 2025 reveals EPS miss, stock drops 10.8% - Investing.com
Organon (OGN) Misses Q4 Earnings and Revenue Estimates - Yahoo Finance
Organon falls as women’s health unit drives Q4 miss (OGN:NYSE) - Seeking Alpha
Organon: Q4 Earnings Snapshot - kare11.com
Organon Q4 Adjusted Earnings, Revenue Fall; 2026 Revenue Outlook Issued - 富途牛牛
Earnings snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook - MSN
Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook - ChartMill
Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations - The Globe and Mail
(OGN) Organon Expects 2026 Revenue About $6.22B, vs. FactSet Est of $6.11B - marketscreener.com
Earnings Flash (OGN) Organon Posts Q4 Revenue $1.51B, vs. FactSet Est of $1.54B - marketscreener.com
Organon shares fall over 5% as Q4 earnings miss expectations By Investing.com - Investing.com South Africa
Press Release: Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 - 富途牛牛
Organon earnings: What to look for from OGN - MSN
Organon Q4 Earnings Preview: Cautious view amid weak year (OGN:NYSE) - Seeking Alpha
Earnings Preview: Organon - Benzinga
Organon & Co. (OGN) Stock Analysis: Exploring A Potential 18.3% Upside In Healthcare - DirectorsTalk Interviews
Organon Q4 Earnings Preview: Revenue Decline Projected Amid Sector VolatilityNews and Statistics - IndexBox
Organon Earnings: What To Look For From OGN - The Chronicle-Journal
Aug Gainers: Does Organon Co meet Warren Buffetts criteria2025 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Organon & Co. (NYSE:OGN) Stock Price Down 5.2%Here's What Happened - MarketBeat
Down 72% In 3 Years, Can Organon Stock Finally Recover In 2026? - TIKR.com
Organon & Co (OGN.US) will release its earnings report before the market opens on February 12. - 富途牛牛
Contraceptive Pills Market Is Going to Boom | Pfizer Inc • Bayer AG • Organon & Co - openPR.com
FDA expands use of Organon’s contraception implant up to 5 years - MSN
Organon & Co. (NYSE:OGN) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
Organon Launches Third Edition of Women's Health Accelerator Program Across Middle East, Turkey & Africa - The Malaysian Reserve
Organon & Co. (OGN) Projected to Post Earnings on Thursday - MarketBeat
Organon Completes Divesture of JADA System to Laborie Medical - MSN
How Organon & Co. (OGN) Affects Rotational Strategy Timing - Stock Traders Daily
Organon & Co: Can This Beaten-Down Women’s Health Specialist Finally Turn a Corner? - AD HOC NEWS
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):